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ABSTRACT
Muslim patients with type 2 diabetes (T2D) who
fast during Ramadan face challenges in diabetes
management due to substantial alterations in
lifestyle and treatment that frequently
accompany the decision to fast. International
guidelines for treating T2D do not fully address
the clinical issues unique to fasting, and other
guidance documents lack the large and
high-quality evidence base available for
non-fasting conditions. We reviewed 10
randomized controlled trials and 20
observational studies in T2D during Ramadan
to assess the quality of evidence and identify
issues in trial design that should be addressed in
future studies. Results indicated that
heterogeneity in key aspects of trial design
precluded meaningful comparisons across
studies. These included patients’ baseline
treatment at entry; use of a cutoff for glycemic
control [glycated hemoglobin (HbA1c)] for
eligibility; exclusion of patients with a history
of recurrent hypoglycemia or hypoglycemia
unawareness, or with other serious systemic
diseases; duration of treatment and follow-up,
selection of safety versus efficacy as primary end
point; and definition and measurement of those
end points. Fructosamine was rarely used as an
efficacy end point, despite the advantage of
reflecting glycemic control over a period more
closely aligned with the duration of Ramadan
fasting than HbA1c. Adherence to treatment,
definition and adherence to fasting, and
changes in diet and exercise were reported
inconsistently, and when reported, not in a
fashion that would allow adequate control of
confounding due to these variables. Despite a
large body of evidence demonstrating their
safety and efficacy in non-fasting populations,
only two trials reported data for glucagon-like
peptide-1 analogs, and neither involved a
head-to-head comparison against dipeptidyl
peptidase-4 inhibitors. More rigorous studies
using trial designs suited to the unique
conditions of a fasting population and
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capturing both standardized efficacy and safety
end points are needed to provide better
guidance to optimal treatment of T2D during
Ramadan fasting.
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INTRODUCTION
Fasting during the holy month of Ramadan is
an important religious obligation for observant
Muslims, and it is estimated that about 79% of
Muslims with type 2 diabetes (T2D) will fast
during Ramadan [1]. Typically, fasting requires
refraining from eating, drinking, and use of
oral and parenteral medications during the
period from 75 min before sunrise to 15 min
after sunset [2–4]. Because the occurrence of
Ramadan follows the lunar calendar, which is
shorter than the Gregorian calendar, the holy
month is observed 10–11 days earlier each year.
When Ramadan falls during the summer
months, the duration of fasting each day
could potentially exceed 20 h for people
living in northern latitudes where the day is
longer [4, 5].
Extended fasting of any sort counteracts
some of the main principles of good diabetes
management, which traditionally involve
careful planning of dietary intake, taking
regular meals and exercise, and aligning these
activities with any medical treatments used to
lower blood glucose, to avoid excessive
hyperglycemia and hypoglycemia. Introducing
fasting while also using glucose-lowering
medications may further challenge diabetes
management, particularly with respect to
hypoglycemia. Indeed, medical opinion
remains divided about whether it is safe, even
for people with well-controlled diabetes, to fast
during Ramadan [6–9]. These safety concerns
are supported by some empirical data. For
example, one large survey of 11,173 Muslims
with T2D, 78.4% of whom were treated with
oral antidiabetic drugs (OADs), indicated that
fasting during Ramadan was associated with a
7.5-fold greater incidence of severe hypoglycemia
(0.03 ± 0.28 vs. 0.004 ± 0.02 episodes/month,
P\0.0001, for fasting vs. non-fasting periods,
respectively) [1]. Fasting was also associated with a
greater incidence of severe hyperglycemia
(0.05 ± 0.35 vs. 0.01 ± 0.05 episodes/month,
respectively, P\0.0001). Nevertheless, Ramadan
is an integral part of life for many Muslims, with
benefits for physical, mental, and social
well-being [10], and many Muslims with T2D
choose to fast during Ramadan, some against
medical advice.
Given that the growing Muslim population
of the world often overlaps with regions where
the incidence of T2D is also increasing rapidly
[11, 12], there is a compelling need for a more
rigorous evidence base to help clinicians make
informed decisions on how to best treat patients
with T2D who wish to fast. For the general
population of patients with T2D, several major
guideline documents have been published,
which include recommendations for newer
treatments, such as drugs of the incretin class
[glucagon-like peptide-1 (GLP-1) analogs and
dipeptidyl peptidase-4 (DPP-4) inhibitors],
which have been shown to have a favorable
balance of safety and efficacy [13, 14].
Although a variety of other guidance
documents have been published offering
recommendations on diabetes management
during religious fasting [3, 15–25], there is
currently no gold standard based on
comprehensive, up-to-date, evidence-based
recommendations. A major reason is that
evidence from clinical trials in non-fasting
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populations, which form the basis for major
international diabetes treatment guidelines, is
not completely transferable to populations who
engage in religious fasting. This is because
fasting during Ramadan typically results in a
variety of changes in lifestyle and treatment,
discussed below, which may disrupt typical
diabetes management practices.
The most consistent changes occurring
during Ramadan fasting include alterations in
the typical between-meal interval, reduced
frequency of meals (e.g., two per day, instead
of three [23, 26]), the type of food eaten (e.g.,
more fried foods and/or the proportion of
energy from carbohydrates such as dates,
juices, and sweets vs. other macronutrients)
[11], and eating a larger volume of food at a
given time if only two meals are consumed.
With respect to consistency of exercise,
long-night Taraweeh prayers lasting 1–2 h,
although not mandatory, can be strenuous
[21]. It has also been noted that fasting during
Ramadan may be associated with changes in
sleep patterns and quality, alertness, and
irritability [5]. It is possible, although currently
speculative, that the stress of coping with these
additional challenges for an entire month could
further compromise a person’s ability to
manage their diabetes effectively.
For patients using OADs, it can be difficult to
coordinate taking medications that must or
may be administered more than once daily
(e.g., some sulfonylurea s or glinides) with an
altered meal schedule [27]. Maintaining
adequate glycemic control when using OADs
may be further complicated if accompanied by
arbitrary patient-initiated changes in dose,
frequency of dosing, and/or timing of
administration of OADs relative to meals, all
of which are believed to be common during
Ramadan [27–29].
There are some promising data on the
efficacy and safety of DPP-4 inhibitors and
GLP-1 analogs of the incretin class during
Ramadan, although results have not always
been entirely consistent. One analysis of 16
published studies concluded that there was
some evidence that DPP-4 inhibitors led to
fewer episodes of hypoglycemia than
sulfonylureas. The analysis, while only
analyzing one trial with a GLP-1 analog,
indicated that GLP-1 analogs also provide
clinical benefits during Ramadan compared
with sulfonylureas [30]. Schweizer et al. [31]
also concluded that DPP-4 inhibitors may be
safe and effective, but a pooled analysis of data
from three randomized controlled trials (RCTs)
suggested that sulfonylureas had similar
incidence of hypoglycemic episodes compared
to DPP-4 inhibitors during Ramadan [32].
Compared to DPP-4 inhibitors, there is less
information regarding the use of GLP-1 analogs
in T2D during Ramadan, with only two trials
currently published. One RCT reported a greater
proportion of subjects achieving the composite
end point of glycated hemoglobin (HbA1c)
\7.0% and weight loss with no severe
hypoglycemic events for liraglutide compared
to sulfonylureas (both in combination with
metformin) [33]. Another RCT has
demonstrated fewer hypoglycemic episodes
with equivalent glycemic control and greater
body weight reduction for liraglutide versus
sulfonylurea (both in combination with
metformin) [34]. With regard to comparisons
of the two classes of incretin drugs, there are
currently no trials comparing DPP-4 inhibitors
and GLP-1 analogs directly during Ramadan.
Choosing the optimal treatment for patients
with T2D requires a robust evidence base; but at
least quantitatively, the volume of evidence
from clinical trials during Ramadan fasting is
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much more limited than that for the general
population of people with T2D. Furthermore,
the quality of the available information, as well
as what might be needed to establish a more
reliable evidence base, is not clear, and some
results appear to be contradictory. Therefore, we
conducted this review to critically examine
published evidence from both RCTs and
observational studies in T2D during Ramadan,
with the goal of summarizing the degree to
which they are consistent in key areas of trial
design. An additional goal was to assess the
comparability of results across trials and
identify inconsistencies or deficiencies that
should be addressed in the design of future
studies. Thus, given our emphasis on
understanding the important contribution of
trial design to the evidence base, efficacy and
safety results per se from individual trials will
not be discussed in detail here.
METHODS
PubMed was searched for the terms ‘‘Ramadan’’
and ‘‘diabetes’’ in either the title or abstract
from 1980 to the present. In total, 197 citations
were retrieved. Abstracts were reviewed, and
papers describing either randomized trials or
observational studies of non-insulin treatments
in T2D during Ramadan and reporting efficacy
and/or safety were retained. In addition, the
bibliographies of retrieved papers were
manually searched to identify any additional
relevant studies. The retrieved studies were
characterized with respect to key aspects of
study design and methodology (e.g.,
populations, OAD treatments used, duration of
trial and period of assessment, choice of end
points and measurement of those end points)
that are particularly pertinent to the unique
aspects of trials of diabetes treatments during
religious fasting, as well as the consistency and
completeness of reporting of these features.
This article is based on previously conducted
studies, and does not involve any new studies of





The key features of study design are presented in
Table 1 for 10 RCTs and in Table 2 for 20
observational studies.
Treatments Studied
Sulfonylureas and drugs of the incretin class
appear to be the most widely studied
non-insulin treatments in comparative trials
during Ramadan. However, individual RCTs
sometimes did not differentiate among the
different sulfonylureas used by patients,
simply grouping different sulfonylureas (e.g.,
gliclazide, glibenclamide, glimepiride; glipizide)
together as a class when reporting results
(Table 1). This may not be appropriate, as
these drugs have durations of actions of
12–18 h, 12–16 h, 12–24 h, and 6–10 h,
respectively [35]. In addition, pooled data
from a number of agents in the sulfonylurea
class mask the different hypoglycemia risks
associated with the individual drugs, as newer
generation sulfonylureas such as gliclazide are
associated with a lower hypoglycemia risk
compared with other sulfonylureas [36]. In
fact, a meta-analysis showed no difference in
hypoglycemia incidence with gliclazide
compared with DPP-4 inhibitors [37]. By
contrast, results for drugs of the incretin class
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have been reported individually for vildagliptin
(two RCTs [38, 39] and five observational
studies [40–44]) for sitagliptin (three RCTs
[45–47]) and liraglutide (two RCTs [33, 34]).
The use of metformin was common, but not
universal (Table 1). Both RCTs using liraglutide
included metformin [33, 34], as did the two
studies using vildagliptin [38, 39] and one of
three RCTs using sitagliptin [45]. However,
metformin was optional for two of the RCTs
using sitagliptin [46, 47] and one trial using
pioglitazone [48]. Metformin was not used in
the two trials examining repaglinide [49, 50].
Treatments used in the observational studies
were quite heterogeneous, with some studies
even combining patients using various
combinations of OADs and/or insulin and/or
diet alone into a single group [51–57] (Table 2).
Eligibility, Number, and Comparability
of Patients
In the RCTs, the number of subjects varied from
41 to 1066. Inclusion and exclusion criteria
were mentioned in some way for all RCTs, but
the level of details presented varied greatly. All
of the RCTs described prior diabetes treatments,
and most of the trials enrolled subjects
previously treated with metformin or
sulfonylurea either as monotherapy or in
combination. However, in a few trials, a
minority of patients had been treated with
thiazolidinediones, glinides, or acarbose
(Table 1). A specific cutoff for glycemic control
(HbA1c) for eligibility was only specified for four
RCTs (7–10% [34]; 6.5–12.0% [33]; B8.5% [38];
B10% [46, 47]). One trial indicated that
participants had to be ‘‘well controlled’’ [45].
Most (n = 7/10) trials excluded patients with a
history of recurrent hypoglycemia, severe
hypoglycemia, or hypoglycemia unawareness
[33, 45–48, 50], but others made no such
exception [38, 39, 49]. Exclusion of patients
with at least some serious systemic diseases was
reported in all but three trials, but the level of
stringency reported varied [39, 47, 49].
There was also a considerable range in the
number of patients participating in the
observational studies (23–1333 patients;
Table 2). With the exception of four reports
[54–56, 58], all of the observational studies
mentioned patient inclusion/exclusion criteria
to some extent. However, as with RCTs, the
stringency of these criteria varied considerably
among studies. For example, some studies
indicated that all patients with T2D were
included [51] or that all consecutive patients
were enrolled [52], whereas others specified
more detailed inclusion criteria such as age,
type of prior treatment, and/or willingness to
fast. Most studies did not specify any HbA1c
cutoff for eligibility, although one required
HbA1c B9.0% [29], two required HbA1c B8.5%
[40, 43], one required HbA1c B8.0% [41], and
one just indicated that patients had to be in
‘‘good control’’ [59].
The same variation was noted with respect to
exclusion criteria, with some observational
studies indicating no exclusion criteria other
than insulin treatment (e.g., [44, 60]) and others
listing very specific exclusion criteria (e.g.,
duration of diabetes, level of glycemic control,
prior treatments, incomplete fasting,
incomplete medical records, and/or serious
renal, hepatic, cerebrovascular or
cardiovascular disease, pregnancy or lactation;
retinopathy, and uncontrolled hypertension
[29, 40, 41, 53, 61, 62]). In contrast to the
RCTs, few observational studies mentioned
excluding patients with severe hypoglycemia
[57], recurrent hypoglycemia [61, 62], or
hypoglycemia unawareness [63], but otherwise
this appeared uncommon. One study using
continuous glucose monitoring (CGM)
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indicated that ‘‘low-risk’’ patients were enrolled
[61].
Choice and Measurement of End Points
The critical factor of end points was not
consistent across studies, either with respect to
the choice or efficacy or safety as a primary end
point, or how those end points were measured.
Three RCTs used a primary efficacy end point
[34, 49, 50] and four RCTs indicated that the
primary end point was a safety end point [38,
45–47], and in two, a primary end point was not
explicitly stated or clear, with multiple efficacy
and safety end points being listed [39, 48]. In
one trial, a specific composite end point was
used [33] (Table 1). In some studies where
efficacy was indicated to be the primary end
point, safety end points were also included.
Conversely, in some studies where safety was
listed as the primary end point, some efficacy
measures were also reported.
When glycemic efficacy end points were
reported, there were also considerable
differences in how they were measured,
ranging from CGM to self-monitored blood
glucose (SMBG), to clinic visits with laboratory
measures, to patient diaries with or without
review by a physician, to phone interviews and
retrospective review of medical records.
Secondary end points such as weight change,
blood pressure, lipids, and quality of life were
inconsistently reported.
Definition of Safety (Hypoglycemia)
Outcomes
In the RCTs, the definition of hypoglycemia, as
well as how hypoglycemia was measured,
varied. Two trials used symptoms only [47,
50]. When a cutoff value was mentioned, most
trials specified a value of\3.9 or B3.9 mmol/L,
although two trials utilized other values
(\3.1 mmol/L [49] and \2.8 mmol/L [50];
Table 1). In one trial, the cutoff point was
unclear [45]. There were also cases where a
primary end point used symptoms as the
criteria, but the results for additional
hypoglycemic end points were also reported
(e.g., [46, 47]).
There was also considerable variability in
how hypoglycemia was defined and measured
in the observational studies (Table 2). Some
studies used patient-reported symptoms only
[29, 51, 57, 60], but more typically used
symptoms with or without blood glucose (BG)
measurements [40, 41, 43, 44, 52, 56, 62]. In
one of these cases, the cutoff was not specified
[56]. The BG cutoff values used were also
heterogeneous (\3.9 mmol/L [40]; B3.9 mmol/L
[41]; 2.8–3.9 mmol/L [53]; \3.9 mmol/L [42];
\3.88 mmol/L [61]; \3.9 mmol/L [43];
\3.5 mmol/L [44]).
Duration of Treatment and Follow-Up
There was great variation in the amount of time
patients were assessed, treated, and followed
across studies. In the RCTs (Table 1), the run-in
period for the non-sulfonylurea treatment
varied considerably, even where patients were
switching to the identical drug. For example,
Anwar et al. [49] reported a 3-month run-in
period for patients switching to repaglinide,
whereas Mafauzy [50] reported 6 weeks. For
three trials using incretins, one with
vildagliptin [39] and two with sitagliptin [46,
47], the duration of the run-in period was
unclear. The duration of follow-up
post-Ramadan, when fasting ceased and
normal diet and lifestyle patterns resumed,
was also variable and sometimes difficult to
discern. For the observational studies (Table 2),
there was also great variation in the length of
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time during which patients were assessed and
data obtained.
Blinding Protocols
Blinding of subjects and evaluators during a
clinical trial is considered an important
protection against bias. Of the 10 RCTs, only
two trials were blinded [38, 48] (Table 1). One
was a double-blind, double-dummy trial [38],
and the other was double-blinded [48]. By
definition, blinding was not possible in the
observational studies.
Definition and Characteristics of Fasting
Fasting was not always explicitly defined in
studies. In the RCTs, the intent to fast was either
stated or assumed based on screening criteria in
nine out of ten trials, but only one trial
indicated a specific minimum amount of time
(i.e., at least 10 days) for fasting [33]. One trial
indicated that participants would be excluded if
they expected to break their fast for [3 days
[50]. It has been reported that the ability to keep
a fast may also depend on the type of treatment
[64], but this was not regularly reported and,
when reported, not in sufficient detail to allow
for meaningful interpretation of the likely
impact of non-adherence on treatment.
Adherence to fasting was not described for six
RCTs [33, 34, 45, 48–50]. When adherence was
reported, the statistic used varied (Table 1). For
example, one study reported the mean number
of days of fasting for the two treatment groups
(i.e., 28.3 ± 3.0 and 28.1 ± 3.8 days) [38],
whereas two other trials reported the
proportion of people in each treatment group
who did not break their fast except to treat
symptoms of hypoglycemia (i.e., 89.7% to
98.4% of participants) [46, 47]. It was often
unclear what constituted an interruption of
fasting, whether an interruption was temporary
or permanent, or under what circumstances an
interruption might be of sufficient duration to
be considered a break in the fast
(non-adherence). For example, one RCT
indicated that eight individuals in one of the
treatment arms broke their fast, but did not
quantify or otherwise describe what that meant
[39].
In the observational studies, intention to fast
(or actual fasting) during Ramadan was either
an implicit or explicit inclusion criteria. In
some cases, the period of intending to fast was
pre-specified in some detail ([10 days [43, 55,
57]; C15 days [61]; C20 days [61]; or throughout
Ramadan [59, 62]). In general, there was more
attention to describing adherence to fasting in
the observational studies, with 13/20 studies
reporting some measure of adherence (Table 2).
This was most frequently framed as the mean
number of days of fasting. However, an
inspection of these mean values in the
table (e.g., from approximately 20.4 to
28.6 days) makes it clear that some
participants did not fast the entire month of
Ramadan.
Ramadan-focused Education and Quality
of Life Assessment
The potential value of patient education has
been evaluated in a number of clinical studies.
For example, patients with T2D using OADs
who received a Ramadan-focused education and
awareness in diabetes (READ) program
demonstrated a decrease in hypoglycemic
episodes during Ramadan [65]. Another
comparative trial in Thailand showed that
patients in the group receiving education prior
to Ramadan significantly reduced the number
of hypoglycemic episodes (P = 0.013), diastolic
blood pressure, (P = 0.041), and consumption
232 Diabetes Ther (2016) 7:221–240
of sweetened food (P = 0.002), and the number
of patients with hypoglycemic symptoms was
also lower (P = 0.013) [66]. A comparison of
patients recruited from clinics in four Muslim
nations who received an individualized
educational program vs. those who did not
showed significant improvements in a variety of
diabetes management outcomes, such as
modifying their treatment plan (P\0.001),
performing SMBG at least twice daily
(P\0.0001), and having improved knowledge
about hypoglycemic signs and symptoms
(P = 0.0007), as well as fewer severe
hypoglycemic events (P = 0.0017) [67]. One
uncontrolled study described the practicality
of implementing a Ramadan-specific
educational program through
diabetes-specialist centers [68]. The study
reported that drug dose and timing were
modified in 90.5% of patients with T2D.
The extent to which Ramadan-focused
education is included in trials whose primary
goal is to compare drug treatment regimens is
unclear. Among the randomized trials
summarized in Table 1, only one study
explicitly mentioned providing
Ramadan-focused education, which was given
to patients in both arms of the trial [38].
However, two other trials mentioned
providing medical counseling regarding risks
of hypoglycemia during fasting [46, 47]. It is
unclear to what degree these issues may have
been raised during the routine informed
consent process in other trials. Among the
observational studies (Table 2), three
mentioned providing Ramadan-focused advice
about diabetes management [42, 44] or
information about the risks associated with
fasting [62], again provided to all patients
participating in the studies. Future trials
should explicitly include and describe the
extent of Ramadan-focused education for
participants.
With regard to patient-reported outcomes
and quality of life assessment, only one of the
reviewed studies assessed treatment satisfaction
and one assessed lifestyle changes [56, 69].
Reporting of Diet and Exercise
Changes in diet and exercise were reported
infrequently, and when reported, typically, this
was not in sufficient detail to enable adequate
account for confounding effects of these changes
when evaluating the efficacy and/or safety of the
treatments being studied. Only one RCT provided
such data, with physical activity assessed by the
International Physical Activity Questionnaire
(IPAQ), and diet information reported in the form
of changes in score for total Metabolic Equivalent
Tasks (METS) for each treatment group [33].
Among the observational studies, as with the
RCTs, reporting of data on diet and exercise was
very limited, with only 3/20 studies providing
information. Siaw et al. [57] reported general
trends in diet and exercise during Ramadan,
describing these only as ‘‘more,’’ ‘‘less,’’ or
‘‘unchanged’’. An analysis of the proportion of
patients reporting reduction (64.7%), increase
(5.9%), or no changes (29.4%) in dietary intake,
as well as data on physical exercise, indicated
that there were no significant associations
between these categories and improvements in
mean HbA1c during fasting. Sahin et al. [56] also
reported similar categorical groupings of
changes in diet and exercise, whereas
Ahmadani et al. [51] reported caloric intake for
1 day before and after fasting, in addition to a
simple dichotomous outcome of diet having
changed or not and exercise having changed or
not. In some cases when it was mentioned in
the Methods section of a paper that information
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on diet and/or exercise was obtained from
patients, the results for those variables were
not presented in the trial report. For example,
Bonakdaran et al. [61] indicated that patients
were required to record dietary programs, time
of meals, quality and quantity of meals, and
time and extent of exercise, but those data were
neither reported nor apparently factored into
the analysis of BG readings or hypoglycemic
events. Zargar et al. [29] also mentioned that
data on meals were obtained, but no results
were presented.
Classes of Diabetes Treatments Studied
The 10 RCTs were heterogeneous with respect
to diabetes treatments evaluated, with five
comparing sulfonylureas to DPP-4 inhibitors,
two comparing sulfonylureas to GLP-1 analogs,
two comparing sulfonylurea to repaglinide, and
one comparing sulfonylurea to pioglitazone
(Table 1). In some cases, only one sulfonylurea
was used, and in others, a variety of
sulfonylureas was permissible. Use of
metformin was inconsistent, with some trials
allowing it, others mandating it, and others
excluding metformin. No RCTs have compared
receptor GLP-1 receptor agonists and DPP-4
inhibitors head-to-head in the treatment of
T2D during Ramadan. This is in contrast to at
least seven such studies published in patients
with T2D not focused on Ramadan fasting (see
[70]). Being a more recently introduced class of
drugs, sodium-glucose co-transporter 2
inhibitors have not yet been studied in fasting
patients with T2D during Ramadan.
Observational studies were even more
heterogeneous with respect to the treatments
studied and it was not uncommon to group
together patients using treatments ranging from
lifestyle management to OADs to insulin, either
individually or in combination (Table 2).
Adherence to Treatment
In the RCTs, adherence to treatment was
difficult to discern. One RCT reported the
proportion of missed doses [38], and others
reported the proportion of patients who
changed the dose or timing of their
medication [46, 47]. One study reported the
proportion of completers reaching the optimal
dose [49], and another reported the proportion
of patients exposed to treatment for [6 and
[10 weeks [50].
Limited reporting of adherence to treatment
was also typical in the observational studies.
When mentioned (6/20 studies), this was
usually brief and in the form of proportion of
patients with missed doses, proportion making
adjustments to dose, or changes in the timing of
dose (e.g., [43, 51, 54, 56, 57, 60]). Few studies
provided detailed measures of adherence (e.g.,
overall adherence per treatment group,
proportion of patients with treatment change
in each group, type of treatment change,
number of times the treatment was not taken,
and/or number of times the treatment was not
taken due to hypoglycemia or fear of
hypoglycemia) [40, 41]. Across these studies,
analysis of how these various measures of
adherence to each treatment were related to
the frequency of hypoglycemic events was
generally lacking.
DISCUSSION
The studies reviewed here, conducted in
populations of Muslims with T2D who fasted
during Ramadan, were quite heterogeneous in
critical components of their design, including
but not limited to patient eligibility and
exclusion criteria, glucose control and
treatments at entry, choice of outcomes
assessed and definitions of those outcomes,
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and method and timing of outcomes
assessment, all of which significantly limit the
ability to compare results across trials. This was
true for RCTs as well as for the observational
studies. Compared with typical diabetes trials in
non-Muslim/non-fasting patients, there appears
to be a trend for trials during Ramadan to
emphasize safety end points over efficacy end
points. The choice of either an efficacy or safety
measure as the primary end point also has
bearing, because a primary end point may be
used for power calculation, which may result in
a study being underpowered to capture other
end points. Efficacy and safety should be
included in the reporting of data, so that
comprehensive information is made available
to clinicians to support clinical decision
making.
With respect to efficacy, the choice of end
point and measurement method should be
aligned with the duration of the trial and
follow-up period. HbA1c is the standard
efficacy end point used in the majority of
longer duration clinical trials and can be
reliably and easily measured. HbA1c reflects
glycemia over the lifespan of red blood cells,
but predominantly glycemia during 6–8 weeks
prior to the time of measurement. This is a
period substantially longer than the duration of
fasting during Ramadan. By comparison,
fructosamine has the ability to assess glycemic
control during shorter periods of assessment
compared to HbA1c, as it reflects average
glycemia the preceding 1–3 weeks [71, 72].
Although fructosamine is not widely used in
clinical trials, it has been used as the primary
end point in a recent RCT with liraglutide, so
clinicians may become more familiar and
comfortable using it [34]. Another validated
short-term marker for glycemic control,
especially for recent postprandial
hyperglycemic excursions and glycemic
variability, is 1,5-anhydroglucitol [73, 74].
Ambulatory glucose monitoring and CGM
offer the possibility of very precise
characterization of daily blood glucose
excursions and allows the possibility of
assessing those changes in light of changes in
diet. The choice of CGM as a tool will need to be
balanced against the increased cost and
complexity associated with its use.
With respect to safety, one obvious concern
for patients with T2D taking glucose-lowering
medications during fasting is the risk of
hypoglycemia. Having a precise, accurate,
and uniform method of assessing
hypoglycemia, as well as clearly defined cut
points, is important for being able to evaluate
trial results and to compare across trials.
Similar entry criteria with respect to history
of hypoglycemia or hypoglycemia
unawareness are essential for comparing the
results of different studies.
Understanding diet and exercise patterns
associated with diabetes treatment is
particularly important for trials conducted
during Ramadan, given that prolonged fasting
involves major changes in routine eating habits
and/or the timing of exercise that may affect
glycemic control. Few of the studies
summarized here reported any diet and
exercise outcomes, and those that did
categorized diet and exercise patterns very
fundamentally (e.g., as increased, decreased,
unchanged) [56, 57]. Such an approach may
be overly simplistic and not capture important
features of changes in diet or exercise.
Furthermore, use of a limited number of
discreet categories would tend to render any
adjustment for confounding by those factors
imprecise, although it should be noted that
such an adjustment was not reported in any of
the trials. How to best assess and control for
changes in diet when the frequency, content,
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and volume of meals may change substantially
over the study period is an unanswered
question. Thorough dietary assessment
involves techniques such as 24-h recall and
food frequency questionnaires (e.g., [75]),
which may be cumbersome to add to a
conventional trial already assessing efficacy
and safety measures.
Adherence to fasting and duration of the
actual fast are important to determine when
studying the effects of treatment on glucose
control. As noted in several studies,
patient-initiated changes in medication timing
or dose, or discontinuation of treatment during
Ramadan, is common [28, 29]. However,
adherence to treatment was often not
reported, and when reported was typically not
assessed relative to the outcome of interest,
regardless of whether efficacy and/or safety
measures were used. It is also critical to
differentiate a stated intention to fast (which
is typically a criterion for enrollment in a RCT)
versus the actual fasting behavior during
Ramadan. For example, the EPIDAIR study
reported that the proportion of subjects fasting
C15 days ranged from 57.8% in Turkey to
89.8% in Malaysia and Bangladesh [1]. It is
sometimes mentioned that participants may
periodically interrupt their fast temporarily if
symptoms of hypoglycemia are experienced,
but the duration of the interruption may not be
specified [68]. As reviewed here, at the time of
enrollment/screening, some patients may
indicate an intention to fast throughout the
entire month of Ramadan, whereas others may
indicate fasting may not last the entire month.
With respect to adherence, the actual duration
of fasting may vary from the stated intention
and be considerably less than the full month of
Ramadan.
CONCLUSIONS
In part due to the degree of heterogeneity in key
aspects of the study design from both RCTs and
observational studies, comparability across
studies remains difficult. Thus, the ideal
treatment regimen for patients with T2D
during Ramadan has not yet been identified.
Given the unique challenges of managing
diabetes during fasting, desirable
characteristics of any treatment might include
flexibility in timing of administration and/or
once-daily dosing (so as not to conflict with
prohibitions during the daytime hours when
taking medications is not possible due to
religious concerns), and a low risk of
hypoglycemia (to better accommodate the
prolonged period of fasting each day).
More definitive trials during Ramadan
fasting, using more evolved trial designs (e.g.,
[34]), are needed to answer important clinical
questions. Trials should include data on a
full range of important clinical end points
(e.g., glycemic control, hypoglycemia,
hyperglycemia, other adverse events, lipid
levels, blood pressure) and quality of life, and
use clearly defined measures that are appropriate
to these end points and time frame. Detailed
assessment of potentially confounding variables
such as changes in diet and exercise are also
required so that appropriate adjustment for these
factors can be performed when assessing
outcomes. Ideally, some trials should also
involve head-to-head comparisons between
DPP-4 inhibitors and GLP-1 analogs. Despite
the limitations of many published studies, there
is evidence suggesting that newer drugs having a
lower risk of hypoglycemia (such as those of the
incretin class) may be beneficial for patients who
choose to fast during Ramadan [30, 31, 34, 76].
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